TMS and the Neurology of Motorneurone Disease
Basic findings
Encompassing the varied forms of diseases affecting the motor neurones, motorneurone disease (MND) includes amyotrophic lateral sclerosis (ALS), progressive bulbar palsy (PBP) and progressive muscular atrophy (PMA). There is sometimes difficulty providing a definitive diagnosis as it relies on ruling out other neurological conditions. TMS has been shown to be a sensitive means for the assessment and monitoring of excitatory and inhibitory upper motor neurone function in MND (Triggs et al 1999, Mancini 2008).
Ongoing findings
Monitoring The Disease
TMS can objectively discriminate corticospinal tract involvement in ALS from controls, which may be used to assess the progression of ALS. Additionally, the decrease in TMS amplitude may provide a useful marker of disease progression (Floyd et al 2009). In summary, TMS provides important diagnostic information for prediction of ALS in MND patients presenting with clinically equivocal UMN impairment, and is currently used in the clinical setting.
Modulating The Disease
It has been proposed that glutamate-related excitotoxicity may promote motor neuron death in ALS. TMS can be used to activate glutamatergic circuits of the motor cortex. rTMS of the motor cortex, at frequencies that decrease cortical excitability, has been shown to cause a slowing in the progression rate of ALS. Evidence has been found that rTMS also contributes to the modulation of MND by stimulating the production of the neural survival factor brain-derived neurotrophic factor (BDNF) (Dileone et al 2010).
Links
References
- Dileone et al., CNS & Neurological Disorders - Drug Targets, 2010.
- Floyd et al., Neurology, 2009.
- Mancini. Chapter XIII. Motor Neuron Disease Research Progress. 2008.
- Triggs et al., Neurology, 1999.